Abstract 1591P
Background
Novel therapies are transforming cancer care. We have previously shown the substantial rise in the number of new oncology treatments approved in the UK over the past decades. However, UK drug approval has changed substantially following Brexit and faced significant challenges during the COVID-19 pandemic. It is unknown how these factors have affected drug approvals and costs.
Methods
The UK core prescribing book is the British National Formulary (BNF) listing all newly approved drugs. We analysed new therapy additions over a 5-year period, collecting data on classification, indication and median treatment duration. To appreciate costs, we calculated the price per treatment and equated this to the UK GDP per capita.
Results
Between 2020-24, 45 new cancer therapies were approved in the UK, comparing favourably with the previous 5-years, when 46 therapies were approved. The past 10-years (2015-24) has seen 91 new cancer therapies approved; a 78.4% increase compared to the previous 10-years (2005-2014). The past 5-years has witnessed continued transition away from cytotoxic chemotherapy (CC) to targeted therapies. In 2005-09 a third of new therapies were CC drugs, compared to only 6.7% in 2020-24. The majority of new approvals over the last 5-years were kinase inhibitors, accounting for 40% (N=18), followed closely by monoclonal antibodies at 35.6% (N=16). The average median duration of treatment is 438 days, increasing substantially from 318 days in 2015-19 and 263 days in 2010-14. The average monthly treatment cost between 2020-24 is £8286.50, increasing from £5937.43 in 2015-19 and £4090.52 in 2010-14. This equates to a 102.6% growth over 15 years. The average total treatment cost in 2020-24 is £119,325.54, almost double compared to 2015-19 (£62,343). This is equivalent to 361.6% of the UK GDP per capita.
Conclusions
Despite Brexit and the COVID-19 pandemic, the UK has maintained a consistent number of new oncology approvals. A transition away from CC towards targeted therapies is fuelling precision oncology. However, as the median duration of treatment and average cost of new therapies continues to rise they pose ongoing significant challenges.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
G. Majhail.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1481P - A case-control study of drug-eluting microspheres and blank microspheres in bronchial artery embolization for hemoptysis in non-small cell lung cancer
Presenter: Tongguo Si
Session: Poster session 10
1482P - Percutaneous transhepatic biliary drainage (PTBD) for palliation of jaundice in patients of unresectable/disseminated carcinoma gall bladder with hilar block: Is it a worthwhile enterprise?
Presenter: Saurabh Galodha
Session: Poster session 10
1484P - Inflammatory patterns of ascites in patients with solid tumors
Presenter: Julia Berger
Session: Poster session 10
1485P - Mitigating symptom clusters of patients with metastatic cancer through a remote physical exercise program (EXIO)
Presenter: Paulo Bergerot
Session: Poster session 10
1486P - A personalized rehabilitation pilot program for improving QOL of unresectable metastatic lung cancer patients
Presenter: Shani Shilo
Session: Poster session 10
1487P - Telemonitoring system effectiveness for alleviating cancer pain in patients with advanced cancer
Presenter: Shiori Yoshida
Session: Poster session 10
1488P - Use of mobile app “SUPPORT+” to enhance community palliative care in advanced cancer patients: A feasibility study
Presenter: Wendy Chan
Session: Poster session 10
1489P - Factors influencing adherence to electronic patient-reported outcomes in palliative cancer care
Presenter: Sarah Gomes
Session: Poster session 10
1490P - Health-related quality of life of cancer patients on chemotherapy and its relationship with caregiver strain: A cross-sectional analytical study
Presenter: Herald Mapa
Session: Poster session 10
Resources:
Abstract